Cornell investigators see promising response for anti-cocaine jab

Researchers are one step closer to testing an anti-cocaine vaccine in people. A novel vaccine developed by a team at Weill Cornell Medical College has shown success at reducing the amount of cocaine that reaches the brain. The vaccine was created by Cornell researchers and is made up of bits of the common cold virus with a particle that mimics the structure of cocaine, spurring an immune response that produces antibodies that target cocaine. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.